NCT02365597 2026-03-19
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT03036098 2026-03-06
CheckMate901
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03390504 2026-02-02
THOR
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05645692 2026-01-30
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT02516241 2026-01-28
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT05366725 2025-12-02
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT04223856 2025-06-13
EV-302
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT00790426 2020-12-19
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
Novartis
Phase 2 Completed
NCT00821327 2016-10-25
Gemzar, Cisp, Sunitinib Urothelial Ca
US Oncology Research
Phase 2 Completed